Rationale: Acute rejection, manifesting as lymphocytic inflammation in a perivascular (acute perivascular rejection [AR]) or peribronchiolar (lymphocytic bronchiolitis [LB]) distribution, is common in lung transplant recipients and increases the risk for chronic graft dysfunction. Objectives: To evaluate clinical factors associated with biopsy-proven acute rejection during the first post-transplant year in a present-day, five-center lung transplant cohort. Methods: We analyzed prospective diagnoses of AR and LB from over 2,000 lung biopsies in 400 newly transplanted adult lung recipients. Because LB without simultaneous AR was rare, our analyses focused on risk factors for AR. Multivariable Cox proportional hazards models were used to assess donor and recipient factors associated with the time to the first AR occurrence.Measurements and Main Results: During the first post-transplant year, 53.3% of patients experienced at least one AR episode. Multivariable proportional hazards analyses accounting for enrolling center effects identified four or more HLA mismatches (hazard ratio [HR], 2.06; P ≤ 0.01) as associated with increased AR hazards, whereas bilateral transplantation (HR, 0.57; P ≤ 0.01) was associated with protection from AR. In addition, Wilcoxon rank-sum analyses demonstrated bilateral (vs. single) lung recipients, and those with fewer than four (vs. more than four) HLA mismatches demonstrated reduced AR frequency and/or severity during the first post-transplant year.Conclusions: We found a high incidence of AR in a contemporary multicenter lung transplant cohort undergoing consistent biopsy sampling. Although not previously recognized, the finding of reduced AR in bilateral lung recipients is intriguing, warranting replication and mechanistic exploration.
Rationale: Acute rejection, manifesting as lymphocytic inflammation in a perivascular (acute perivascular rejection [AR]) or peribronchiolar (lymphocytic bronchiolitis [LB]) distribution, is common in lung transplant recipients and increases the risk for chronic graft dysfunction. Objectives: To evaluate clinical factors associated with biopsy-proven acute rejection during the first post-transplant year in a present-day, five-center lung transplant cohort. Methods: We analyzed prospective diagnoses of AR and LB from over 2,000 lung biopsies in 400 newly transplanted adult lung recipients. Because LB without simultaneous AR was rare, our analyses focused on risk factors for AR. Multivariable Cox proportional hazards models were used to assess donor and recipient factors associated with the time to the first AR occurrence.Measurements and Main Results: During the first post-transplant year, 53.3% of patients experienced at least one AR episode. Multivariable proportional hazards analyses accounting for enrolling center effects identified four or more HLA mismatches (hazard ratio [HR], 2.06; P ≤ 0.01) as associated with increased AR hazards, whereas bilateral transplantation (HR, 0.57; P ≤ 0.01) was associated with protection from AR. In addition, Wilcoxon rank-sum analyses demonstrated bilateral (vs. single) lung recipients, and those with fewer than four (vs. more than four) HLA mismatches demonstrated reduced AR frequency and/or severity during the first post-transplant year.Conclusions: We found a high incidence of AR in a contemporary multicenter lung transplant cohort undergoing consistent biopsy sampling. Although not previously recognized, the finding of reduced AR in bilateral lung recipients is intriguing, warranting replication and mechanistic exploration.
Authors: Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen Journal: J Heart Lung Transplant Date: 2018-09-25 Impact factor: 10.247
Authors: Daniel C Chambers; Roger D Yusen; Wida S Cherikh; Samuel B Goldfarb; Anna Y Kucheryavaya; Kiran Khusch; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Joseph W Rossano; Josef Stehlik Journal: J Heart Lung Transplant Date: 2017-07-19 Impact factor: 10.247
Authors: Matthias Peltz; Leah B Edwards; Michael E Jessen; Fernando Torres; Dan M Meyer Journal: J Heart Lung Transplant Date: 2010-12-08 Impact factor: 10.247
Authors: Chunshui He; Soren Schenk; Qiwei Zhang; Anna Valujskikh; Jörg Bayer; Robert L Fairchild; Peter S Heeger Journal: J Immunol Date: 2004-01-01 Impact factor: 5.422
Authors: Peter M Hopkins; Christina L Aboyoun; Prashant N Chhajed; Monique A Malouf; Marshall L Plit; Stephen P Rainer; Allan R Glanville Journal: Am J Respir Crit Care Med Date: 2004-08-05 Impact factor: 21.405
Authors: Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Allan R Glanville; Christina L Aboyoun; Adrian Havryk; Marshall Plit; Steven Rainer; Monique A Malouf Journal: Am J Respir Crit Care Med Date: 2008-02-08 Impact factor: 21.405
Authors: Michael Y Shino; Jamie L Todd; Megan L Neely; Jerry Kirchner; Courtney W Frankel; Laurie D Snyder; Elizabeth N Pavlisko; Gregory A Fishbein; Joanna M Schaenman; Kristen Mason; Karen Kesler; Tereza Martinu; Lianne G Singer; Wayne Tsuang; Marie Budev; Pali D Shah; John M Reynolds; Nikki Williams; Mark A Robien; Scott M Palmer; S Sam Weigt; John A Belperio Journal: Am J Transplant Date: 2022-06-15 Impact factor: 9.369
Authors: Claire C Cutting; Willis S Bowman; Nam Dao; Janelle Vu Pugashetti; Christine Kim Garcia; Justin M Oldham; Chad A Newton Journal: Chest Date: 2021-01-21 Impact factor: 9.410